Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 8.01 (Other Events). AZURE-4 met its Week 24 primary endpoint: 59% at 300 mg QW and 44% at 900 mg Q4W versus 0% delayed treatment.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- AZURE-4 met its Week 24 primary endpoint: 59% at 300 mg QW and 44% at 900 mg Q4W versus 0% delayed treatment
- Positive result completes the second Phase 3 study supporting brelovitug’s planned U.S. registration package
- Long-term data showed higher combined responses, reaching 100% at 108 weeks in a 900 mg Phase 2a cohort with cirrhosis
- Safety profile remained consistent, with flu-like illness in 17.2% and 18.5% of participants by dose group
- BLA submission planned for the first half of 2027, with potential U.S. launch in Q4 2027 if approved
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.